The Radiology Business Journal (7/9, Slachta) reports researchers found that “adding contrast-enhanced ultrasound (US) to traditional US could promote better, more sensitive detection and diagnosis of breast lesions.” The findings were published in Clinical Radiology. The study’s authors said that the American College of Radiology’s Breast Imaging-Reporting and Data System (BI-RADS) “has standardized the treatment process and improved the diagnosis efficiency of breast lesions worldwide. However, the low specificity troubles clinicians.”
The Radiology Business Journal (7/6, Walter) reported researchers found that “optoacoustic ultrasound can help radiologists improve the specificity of breast imaging without leading to a loss in sensitivity.” The findings were published in the American Journal of Roentgenology.
STAT (7/5, Faber) reports a study published in JAMA Oncology “suggests that women might benefit from individualized approaches to mammograms rather than from universal guidelines.” Researchers revealed that, “As fewer women were screened, both the number of overdiagnosed breast cancer decreased, as did the number of breast cancer deaths prevented by screening,” and that the new method “might even be more cost-effective.” Also covering the story are Medscape (7/5, Mulcahy, Subscription Publication), the Radiology Business Journal (7/5, Walter), Aunt Minnie (7/5, Ward).
The Radiology Business Journal (7/3, Walter) reported the American College of Radiology Commission on Breast Imaging “sent a letter to the Physician Data Query (PDQ) Editorial Board objecting to specific language included in the recently updated Breast Cancer Screening PDQ.” Dana H. Smetherman, MD, MPH, MBA, chair of the ACR Commission on Breast Imaging, and Kelly Biggs, MD, chair of the ACR Committee on Government Relations, signed the two-page letter. Smetherman and Biggs ended the letter saying, “We would welcome the opportunity to discuss this matter with you in more detail and to provide additional information or respond to specific questions you may have.”
HealthImaging (7/2, O'Connor) reports on a clinical trial being started at the University of Kansas Cancer Center, in which researchers are “recruiting post-menopausal women at least 50 years old who are in the early stages of human epidermal growth factor receptor 2 (HER2) positive invasive ductal carcinoma and also have clear lymph nodes.” The patients will decide whether to join “the intervention group (no radiation) or the control group,” who will receive radiation. Melissa Mitchell, MD, PhD, who is leading the trial, said, “The treatment drugs have just become so effective that it made us think that maybe we could scale back and spare patients the side effects of radiation.”